SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

AFJK is generating intense community conversation, characterized by extremely high volatility and speculative trading, as it continues to exhibit patterns seen in other low-float, China-linked stocks that have recently experienced dramatic price movements. Many traders are chasing potential explosive gains, while others caution about the stock's "pump and dump" reputation and the significant risks of rapid reversals and trading halts.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending amid a sharp stock price decline to 52-week lows, sparking intense debate among investors. Bulls emphasize strong fundamentals like a $1.4 billion contract and robust financials, while attributing the suppressed price to alleged manipulation and purchasing restrictions by major brokerage firms, fueling expectations of a future squeeze. Skeptics, however, point to management's communication issues and past perceived misleading announcements, questioning the company's ability to translate business growth into shareholder value.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending amid a broader 'SPAC mania,' with traders highlighting its extremely low float as a key catalyst for potential explosive price action. The community is actively comparing ESHA to recent low-float SPAC runners like AFJK and ASPC, anticipating a significant sympathy play or short squeeze. This has generated intense speculative interest, despite some underlying skepticism, as many expect ESHA to follow its peers with parabolic gains.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending, fueled by an exceptionally active and dedicated community passionately championing the "OG meme" narrative of Rage Comics. This committed base is consistently building out an ecosystem with tools like RageMaker and RageGames, aiming to onboard new users into crypto, while expressing strong conviction for significant long-term growth and widespread recognition within the market.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following its recent FDA approval of NEREUS (tradipitant), marking the first new motion sickness drug in nearly 40 years. The community is buzzing with excitement over its significant potential to address GLP-1 induced nausea and vomiting, fueling widespread speculation about a potential buyout by major pharma and a substantial re-rating of the stock's valuation. Investors are largely bullish, anticipating further upside driven by this approval and additional pipeline catalysts.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is actively discussed after China officially extended EV trade-in subsidies into 2026, offering significant incentives for new energy vehicle purchases. This policy tailwind, combined with strong delivery growth for its ES8 model and continuous expansion of its battery swap network, is fueling community optimism about the company's path to profitability, while also driving conversations around perceived market manipulation.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing extreme volatility due to the CME's recent margin hikes and impending Chinese export restrictions on silver, fueling intense market speculation. Bulls are aggressively anticipating a significant short squeeze, citing growing industrial demand from sectors like AI and a decoupling of physical versus paper market prices. Conversely, bears warn of an orchestrated pump-and-dump, predicting sharp corrections as leveraged positions face potential liquidation.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co

Alpha Capital Acquisition Co. (ASPC) is trending with intense speculative interest, driven by community comparisons to recent low-float "Chinese SPAC" stocks that have experienced significant price volatility. Discussion is highly polarized between those anticipating a massive short squeeze due to high borrow rates and others warning of a potential pump-and-dump scenario. This dual narrative of extreme bullishness and caution, fueled by historical patterns of similar tickers, is generating considerable buzz.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics Holdings is trending due to its proposed business combination with Applied Digital Cloud to form ChronoScale Corporation, an entity focused on AI-accelerated computing infrastructure. This catalyst has sparked intense community discussion, with many anticipating significant upside from the AI sector and low float dynamics, while a strong counter-narrative raises concerns about potential shareholder dilution and the merger's unfavorable terms for existing EKSO holders.

Themes ETF Trust - Leverage Shares 2X Long UNH Daily ETF

Leverage Shares 2X Long UNH Daily ETF

The Leverage Shares 2X Long UNH Daily ETF (UNHG) is facing significant community backlash following an unexpected dividend event that caused a sharp decline in its value, despite the underlying UNH stock remaining relatively stable. Investors are expressing widespread confusion and frustration, with many labeling the event as "scam," "decay," or "manipulation," leading to intense debate over the legitimacy and operational transparency of this new leveraged ETF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors

Altai Capital Management, L.P. (Altai), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (OraSure or the...

Systematic Financial Management LP Increases Holdings in OraSure Technologies, Inc. $OSUR

Systematic Financial Management LP grew its position in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 35.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The...

Private Management Group Inc. Has $16.38 Million Holdings in OraSure Technologies, Inc. $OSUR

Private Management Group Inc. grew its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 23.6% in the 2nd quarter, according to the company in its most recent Form 13F...

Stephens Lowers OraSure Technologies (NASDAQ:OSUR) Price Target to $3.00

Stephens lowered their target price on shares of OraSure Technologies from $3.50 to $3.00 and set an "equal weight" rating on the stock in a research note on Wednesday...

Acadian Asset Management LLC Lowers Position in OraSure Technologies, Inc. $OSUR

Acadian Asset Management LLC lowered its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 20.4% during the second quarter, according to the company in its most recent...

OraSure Technologies (NASDAQ:OSUR) Posts Earnings Results

OraSure Technologies (NASDAQ:OSUR - Get Free Report) issued its earnings results on Wednesday. The medical instruments supplier reported ($0.17) EPS for the quarter, missing the consensus estimate of...

OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of +18.75% and -7.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

InfuSystems Holdings, Inc. (INFU) Tops Q3 Earnings Estimates

InfuSystems Holdings (INFU) delivered earnings and revenue surprises of +37.50% and -1.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Tilray Brands, Inc. (TLRY) Reports Break-Even Earnings for Q1

Tilray Brands (TLRY) delivered earnings and revenue surprises of +100.00% and +1.29%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

Altai Capital Management is reportedly preparing to launch a board fight at medical device company OraSure Technologies (OSUR).The hedge fund is one of the biggest owners of OraSure and built up its stake from 3% at the end of June to 5% in recent weeks, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/transactional/altai-capital-lays-groundwork-board-fight-orasure-technologies-sources-say-2025-09-09/">reported</a>, citing two people familiar with the matter.The larger stake allows Altai to press its case for board representation more forcefully, the people told Reuters. Two OraSure directors will stand for reelection at next year's annual meeting, and Altai is likely to nominate two candidates, including its founder, Rishi Bajaj, at some point, the report stated. Bajaj last year suggested that an investor with experience in capital allocation should join the OraSure board, the sources told Reuters.Shares of the company traded 2% higher at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/OSUR">OSUR stock</a> remained in ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_12_44_48_PM_png_7a065a0f80.webp" alt="OSUR's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>OSUR's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes it’s ‘good news’.<stembedurl>https://stocktwits.com/Gantz7/message/627948069</stembedurl>However, another user cheered for the Altai founder.<stembedurl>https://stocktwits.com/AnonMav/message/627979684</stembedurl>Last month, Reuters reported that OraSure Technologies (OSUR) received a letter from healthcare entrepreneur Ron Zwanziger stating that he may pursue a more "adversarial path" if the board continues to resist his offer to buy the company.Zwanziger made an unsolicited all-cash offer to buy OraSure for between $3.50 and $4.00 a share in June but was rebuffed. The entrepreneur stated in his letter that other investors have grown concerned and reached out to him."If the board is not willing to entertain a collaborative discourse, we will be left with no choice but to consider all alternatives available," the letter <a href="https://stocktwits.com/news-articles/markets/equity/orasure-receives-warning-from-ron-zwanziger/chssxJ9RdS9">said</a>, without detailing the alternative options. "We would prefer to work together with you in a collaborative fashion to realize the full value potential for all shareholders, rather than pursuing a more adversarial path," the letter stated, as per the report. However, Altai and Zwanziger are not working together, Reuters said on Tuesday.For the three months through the end of June, OraSure’s total net revenues fell 43% year-on-year to $31.24 million, while diluted and adjusted loss per share stood at $0.19 compared to a profit of $0.08 in the corresponding quarter of 2024.OSUR stock is down 8% this year and approximately 21% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-tesla-q3-deliveries-to-exceed-wall-street-estimates-but-sees-full-year-numbers-slip/chwK7ojRdtl">Gary Black Expects Tesla Q3 Deliveries To Exceed Wall Street Estimates But Sees Full-Year Numbers Slip: Retail’s Divided On Stock Performance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Hedge Fund Reportedly Prepares To Launch Board Fight At OraSure Technologies: Retail Investors Believe It’s Good News

Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters reported.  

Equity

Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters reported.  


OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

Current Price	$2.47
Prev Close	$2.43
Open	$2.44
Dividend Yield	0.00%
50-Day Moving Average	$2.51
Beta	1.11
Avg. Volume	813,835.79
PE Ratio	-3.05

52-Week High	$4.22
52-Week Low	$2.08
Market Capitalization	$174.31M
EPS (Annual)	-$0.262
Price to Book	0.49
Revenue Per Employee	$370,912.18
Enterprise Value/EBITDA	N/A

OSUR
Orasure Technologies Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OSUR News

OSUROrasure Technologies Inc.